Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR1 | P32246 | 2/20 | 0.40 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.39 |
| ▸ | IDO1 | P14902 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | PPARG | P37231 | 5/20 | 0.36 |
| ▸ | PDE2A | O00408 | 1/20 | 0.35 |
| ▸ | AKT1 | P31749 | 3/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1285197 | 1.00 | CCR1 (0.40) | CCR1SCN9AIDO1TDP1MEN1 | |
| SCHEMBL1285546 | 0.89 | CCR1 (0.36) | CCR1PPARGPDE2AAKT1 | |
| SCHEMBL1285544 | 0.89 | CCR1 (0.36) | CCR1PPARGPDE2AAKT1 | |
| SCHEMBL1643305 | 0.86 | CCR1 (0.41) | CCR1IDO1MEN1KMT2APPARG | |
| SCHEMBL1285150 | 0.84 | PDE2A (0.42) | CCR1PPARGPDE2A | |
| SCHEMBL10271858 | 0.82 | PDE2A (0.46) | MEN1KMT2APPARGPDE2A | |
| SCHEMBL1643661 | 0.75 | CCR1 (0.37) | CCR1IDO1PPARGPDE2AAKT1 | |
| SCHEMBL1284987 | 0.73 | PDE2A (0.45) | MEN1KMT2APDE2A | |
| SCHEMBL1285400 | 0.73 | PDE2A (0.45) | MEN1KMT2APDE2A | |
| SCHEMBL1643007 | 0.73 | PDE2A (0.47) | CCR1PPARGPDE2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120088746-A1 | AMIDE DERIVATIVES AS ION-CHANNEL LIGANDS AND PHARMACEUTICAL COMPOSITIONS AND METHODS OF USING THE SAME | PFIZER INC. (US) | 2012-04-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120088746-A1 | AMIDE DERIVATIVES AS ION-CHANNEL LIGANDS AND PHARMACEUTICAL COMPOSITIONS AND METHODS OF USING THE SAME | TRPV1, TRPA1, TRPV2 | CCR1 1255/4885SCN9A 126/4885IDO1 3128/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.